shouguang fukang pharmaceutical co.,ltd

Founded in 1993, Shouguang Fukang is a premier research and technology driven Chinese pharmaceutical enterprise with demonstrated capabilities for new drug research and development. It is ranked 42nd among China's Pharmaceutical Industry, employs 3,000 people and has a manufacturing campus of over 300 acres (2,000 Chinese acre).

Shouguang Fukang Pharmaceutical Co., Ltd. specializes in the development, manufacturing and marketing of 5 core product categories. They are PHARMACEUTCAL API, INTERMEDITES and FINISHED DOSE as well as BROMIDE COMPOUNDS and PAPER ADDITIVES, with a total of more than 60 products. Our production and sales volume of the API, trimethoprim (TMP), accounts for more than 70% of the world market. We are the No. 1 domestic producer and marketer of omeprazole, sulfamethoxazole (SMZ) and metformin HCl and the largest production base of bromide compounds. In a joint venture with BASF, we produce the following paper additives ; ODB-II, ODB-I, S-205 and EGTE, to the highest international standards.

Shouguang Fukang has established and implemented comprehensive quality assurance and quality control systems, with certifications of ISO9001/14001 and OHSAS18001. Shouguang Fukang was one of the first companies to receive SFDA GMP certification and five of our APIs, TMP, SMZ, omeprazole, metformin HCl and clozapine, have successfully passed USFDA inspection in Year 2011. We also gained COS certification from the European Directorate for the Quality of Medicines (EDQM). In addition we have successfully passed quality site audits from numerous renowned multinational corporations. Our company's products are domestically sold in 26 provinces and are exported to over 60 countries worldwide.